<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536405</url>
  </required_header>
  <id_info>
    <org_study_id>V221-027</org_study_id>
    <secondary_id>P20930</secondary_id>
    <nct_id>NCT01536405</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)</brief_title>
  <official_title>A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety, tolerability, and immunogenicity of measles, mumps,
      rubella, and varicella (MMRV) vaccine made with an alternative manufacturing process with
      those of the 2006 process
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels &gt;=5 gpELISA Units/mL</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for VZV Immunoglobulin (IgG) antibody levels by a glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Measles Virus Antibody Levels &gt;=255 mIU/mL</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for measles virus IgG antibody levels by an ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Mumps Virus Antibody Levels &gt;=10 Units/mL</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for mumps virus IgG antibody levels by an enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Rubella Virus Antibody Levels &gt;=10 International Units/mL (IU/mL)</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for rubella virus IgG antibody levels by an ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of VZV Antibodies</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for VZV IgG antibody levels by gpELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Measles Virus Antibodies</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for measles virus IgG antibody levels by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Mumps Virus Antibodies</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for mumps virus IgG antibody levels by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Rubella Virus Antibodies</measure>
    <time_frame>Six weeks after vaccination 1</time_frame>
    <description>Sera were tested for rubella virus IgG antibody levels by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Fever (&gt;=102.2°F [39.0°C] or Oral Equivalent)</measure>
    <time_frame>Up to 5 days after vaccination 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Fever (&gt;=102.2°F [39.0°C] or Oral Equivalent)</measure>
    <time_frame>Up to 42 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Zoster-like Rash</measure>
    <time_frame>Up to 42 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mumps-like Symptoms</measure>
    <time_frame>Up to 42 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Measles-like Rash</measure>
    <time_frame>Up to 42 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rubella-like Rash</measure>
    <time_frame>Up to 42 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Varicella-like Rash</measure>
    <time_frame>Up to 42 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Injection-site Adverse Event</measure>
    <time_frame>Up to 5 days after each vaccination</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs reported were solicited with a Vaccine Report Card.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1412</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>MMRV (AMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMRV (2006 process)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMRV (AMP)</intervention_name>
    <description>Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.</description>
    <arm_group_label>MMRV (AMP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMRV (2006 process)</intervention_name>
    <description>Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.</description>
    <arm_group_label>MMRV (2006 process)</arm_group_label>
    <other_name>ProQuad™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Negative clinical history for measles, mumps, rubella, varicella, and zoster

        Exclusion Criteria:

          -  Received any measles, mumps, rubella, or varicella vaccine, either alone or in any
             combination at any time prior to the study, or is anticipated to receive any of these
             vaccines outside of study protocol, either alone or in any combination, during the
             study

          -  Received immune globulin, a blood transfusion or blood-derived products (does not
             include autologous blood/blood products) within 5 months (150 days) prior to any dose
             of the study vaccines or plans to receive these products while enrolled in this study

          -  Exposed to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the
             study vaccination

          -  Any congenital or acquired immune deficiency, neoplastic disease, or depressed
             immunity, including that resulting from steroid use or other immunosuppressive therapy

          -  Received 1) systemic immunomodulatory steroids [greater than the

        equivalent of 2 mg/kg total daily dose of prednisone] within 3 months prior to

        entering the study, or 2) any dose of systemic immunomodulatory steroids within

        7 days prior to entering study, or 3) is expected to require systemic immunomodulatory
        steroids through the course of the study

          -  History of allergy or anaphylactoid reaction to gelatin, sorbitol, neomycin, egg
             proteins (eggs or egg products), chicken proteins, or any component of the study
             vaccines

          -  Received salicylates (eg, aspirin or aspirin-containing products) within 14 days prior
             to study vaccination

          -  Diagnosis of an active neurological disorder. Enrollment may be considered

        when the disease process has been stabilized

          -  History of seizure disorder, including single febrile seizure

          -  Diagnosis of active untreated tuberculosis

          -  History of thrombocytopenia

          -  Born to a human immunodeficiency virus (HIV) infected mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Marshall GS, Senders SD, Shepard J, Twiggs JD, Gardner J, Hille D, Hartzel J, Valenzuela R, Stek JE, Helmond FA. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process. Hum Vaccin Immunother. 2016 Aug 2;12(8):2188-2196. Epub 2016 May 5.</citation>
    <PMID>27149048</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <results_first_submitted>May 30, 2014</results_first_submitted>
  <results_first_submitted_qc>May 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Mumps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=V221-027&amp;kw=V221-027&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant was inadvertently randomized twice, for a total of 1413 randomizations. The Participant Flow reported below includes this participant only once.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MMRV (AMP)</title>
          <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
        </group>
        <group group_id="P2">
          <title>MMRV (2006 Process)</title>
          <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization to Visit 1 (Vaccination 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="706"/>
                <participants group_id="P2" count="706"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="698"/>
                <participants group_id="P2" count="702"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 1 (Vaccination 1) to Visit 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="698"/>
                <participants group_id="P2" count="702"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="698"/>
                <participants group_id="P2" count="702"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="666"/>
                <participants group_id="P2" count="662"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 2 to Visit 3 (Vaccination 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="666"/>
                <participants group_id="P2" count="662"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="635"/>
                <participants group_id="P2" count="634"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 3 (Vaccination 2) to Visit 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="635"/>
                <participants group_id="P2" count="634"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="634"/>
                <participants group_id="P2" count="632"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="615"/>
                <participants group_id="P2" count="618"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 4 to Extended Study Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="615"/>
                <participants group_id="P2" count="618"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="595"/>
                <participants group_id="P2" count="595"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MMRV (AMP)</title>
          <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
        </group>
        <group group_id="B2">
          <title>MMRV (2006 Process)</title>
          <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="706"/>
            <count group_id="B2" value="706"/>
            <count group_id="B3" value="1412"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.4" spread="2.2"/>
                    <measurement group_id="B2" value="13.6" spread="2.5"/>
                    <measurement group_id="B3" value="13.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="344"/>
                    <measurement group_id="B2" value="324"/>
                    <measurement group_id="B3" value="668"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="382"/>
                    <measurement group_id="B3" value="744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels &gt;=5 gpELISA Units/mL</title>
        <description>Sera were tested for VZV Immunoglobulin (IgG) antibody levels by a glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination VZV serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels &gt;=5 gpELISA Units/mL</title>
          <description>Sera were tested for VZV Immunoglobulin (IgG) antibody levels by a glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination VZV serology results</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="95.6" upper_limit="98.4"/>
                    <measurement group_id="O2" value="93.0" lower_limit="90.7" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% confidence interval (CI) on the risk difference excluding a decrease &gt;= the prespecified criterion of 10 percentage points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
            <estimate_desc>RD = MMRV (AMP) - MMRV (2006 process)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Acceptability of the antibody response rate was based on a lower bound of the 95% CI being &gt;76%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sample binomial</method>
            <param_type>Response rate</param_type>
            <param_value>97.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.6</ci_lower_limit>
            <ci_upper_limit>98.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Measles Virus Antibody Levels &gt;=255 mIU/mL</title>
        <description>Sera were tested for measles virus IgG antibody levels by an ELISA</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination measles virus serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Measles Virus Antibody Levels &gt;=255 mIU/mL</title>
          <description>Sera were tested for measles virus IgG antibody levels by an ELISA</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination measles virus serology results</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="94.9" upper_limit="97.9"/>
                    <measurement group_id="O2" value="98.9" lower_limit="97.7" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% CI on the risk difference excluding a decrease &gt;= the prespecified criterion of 5 percentage points</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>RD = MMRV (AMP) - MMRV (2006 process)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Acceptability of the antibody response rate was based on a lower bound of the 95% CI being &gt;90%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sample binomial</method>
            <param_type>Response rate</param_type>
            <param_value>96.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.9</ci_lower_limit>
            <ci_upper_limit>97.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Mumps Virus Antibody Levels &gt;=10 Units/mL</title>
        <description>Sera were tested for mumps virus IgG antibody levels by an enzyme-linked immunosorbent assay (ELISA)</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination mumps virus serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mumps Virus Antibody Levels &gt;=10 Units/mL</title>
          <description>Sera were tested for mumps virus IgG antibody levels by an enzyme-linked immunosorbent assay (ELISA)</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination mumps virus serology results</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="610"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="96.8" upper_limit="99.1"/>
                    <measurement group_id="O2" value="97.2" lower_limit="95.6" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% CI on the risk difference excluding a decrease &gt;= the prespecified criterion of 5 percentage points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>RD = MMRV (AMP) - MMRV (2006 process)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Acceptability of the antibody response rate was based on a lower bound of the 95% CI being &gt;90%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sample binomial</method>
            <param_type>Response rate</param_type>
            <param_value>98.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.8</ci_lower_limit>
            <ci_upper_limit>99.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rubella Virus Antibody Levels &gt;=10 International Units/mL (IU/mL)</title>
        <description>Sera were tested for rubella virus IgG antibody levels by an ELISA</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination rubella serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rubella Virus Antibody Levels &gt;=10 International Units/mL (IU/mL)</title>
          <description>Sera were tested for rubella virus IgG antibody levels by an ELISA</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination rubella serology results</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="593"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="97.6" upper_limit="99.5"/>
                    <measurement group_id="O2" value="99.3" lower_limit="98.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% CI on the risk difference excluding a decrease &gt;= the prespecified criterion of 5 percentage points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>RD = MMRV (AMP) - MMRV (2006 process)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Acceptability of the antibody response rate was based on a lower bound of the 95% CI being &gt;90%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sample binomial</method>
            <param_type>Response rate</param_type>
            <param_value>98.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.6</ci_lower_limit>
            <ci_upper_limit>99.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of VZV Antibodies</title>
        <description>Sera were tested for VZV IgG antibody levels by gpELISA</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination VZV serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of VZV Antibodies</title>
          <description>Sera were tested for VZV IgG antibody levels by gpELISA</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination VZV serology results</population>
          <units>ELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="16.4" upper_limit="18.3"/>
                    <measurement group_id="O2" value="14.4" lower_limit="13.6" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% CI on the GMT ratio, excluding a decrease of &gt;=1.5 fold</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Analysis was based on log-transformed titers</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>GMT ratio = MMRV (AMP) / MMRV (2006 process)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Measles Virus Antibodies</title>
        <description>Sera were tested for measles virus IgG antibody levels by ELISA</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination measles virus serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Measles Virus Antibodies</title>
          <description>Sera were tested for measles virus IgG antibody levels by ELISA</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination measles virus serology results</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3426.5" lower_limit="3162.5" upper_limit="3712.4"/>
                    <measurement group_id="O2" value="3719.5" lower_limit="3506.0" upper_limit="3946.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% CI on the GMT ratio, excluding a decrease of &gt;=1.5 fold</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Analysis was based on log-transformed titers</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>GMT ratio = MMRV (AMP) / MMRV (2006 process)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Mumps Virus Antibodies</title>
        <description>Sera were tested for mumps virus IgG antibody levels by ELISA</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination mumps virus serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Mumps Virus Antibodies</title>
          <description>Sera were tested for mumps virus IgG antibody levels by ELISA</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination mumps virus serology results</population>
          <units>Mumps Ab units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="610"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.1" lower_limit="104.1" upper_limit="120.7"/>
                    <measurement group_id="O2" value="114.0" lower_limit="105.8" upper_limit="122.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% CI on the GMT ratio, excluding a decrease of &gt;=1.5 fold</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Analysis was based on log-transformed titers</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>GMT ratio = MMRV (AMP) / MMRV (2006 process)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Rubella Virus Antibodies</title>
        <description>Sera were tested for rubella virus IgG antibody levels by ELISA</description>
        <time_frame>Six weeks after vaccination 1</time_frame>
        <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination rubella virus serology results</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Rubella Virus Antibodies</title>
          <description>Sera were tested for rubella virus IgG antibody levels by ELISA</description>
          <population>The per protocol population included participants who received &gt;=1 dose of study vaccine, were seronegative at baseline and had postvaccination rubella virus serology results</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="593"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="76.8" upper_limit="87.2"/>
                    <measurement group_id="O2" value="80.7" lower_limit="76.4" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority evaluation is based on the lower bound of the 2-sided 95% CI on the GMT ratio, excluding a decrease of &gt;=1.5 fold</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Analysis was based on log-transformed titers</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>GMT ratio = MMRV (AMP) / MMRV (2006 process)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Fever (&gt;=102.2°F [39.0°C] or Oral Equivalent)</title>
        <time_frame>Up to 5 days after vaccination 1</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fever (&gt;=102.2°F [39.0°C] or Oral Equivalent)</title>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="648"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>RD = MMRV (AMP) - MMRV (2006 process)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Fever (&gt;=102.2°F [39.0°C] or Oral Equivalent)</title>
        <time_frame>Up to 42 days after each vaccination</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fever (&gt;=102.2°F [39.0°C] or Oral Equivalent)</title>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="650"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination 1; n=650, n=649</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination 2; n=592, n=597</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Zoster-like Rash</title>
        <time_frame>Up to 42 days after each vaccination</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Zoster-like Rash</title>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination 1; n=682, n=682</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination 2; n=634, n=632</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mumps-like Symptoms</title>
        <time_frame>Up to 42 days after each vaccination</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mumps-like Symptoms</title>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination 1; n=682, n=682</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination 2; n=634, n=632</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Measles-like Rash</title>
        <time_frame>Up to 42 days after each vaccination</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Measles-like Rash</title>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination 1; n=682, n=682</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination 2; n=634, n=632</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rubella-like Rash</title>
        <time_frame>Up to 42 days after each vaccination</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rubella-like Rash</title>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination 1; n=682, n=682</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination 2; n=634, n=632</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Varicella-like Rash</title>
        <time_frame>Up to 42 days after each vaccination</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Varicella-like Rash</title>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination 1; n=682, n=682</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination 2; n=634, n=632</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Injection-site Adverse Event</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs reported were solicited with a Vaccine Report Card.</description>
        <time_frame>Up to 5 days after each vaccination</time_frame>
        <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV (AMP)</title>
            <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
          </group>
          <group group_id="O2">
            <title>MMRV (2006 Process)</title>
            <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Injection-site Adverse Event</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs reported were solicited with a Vaccine Report Card.</description>
          <population>The population analyzed included participants who received &gt;=1 study vaccination and had follow-up safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination 1; n=682, n=682</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                    <measurement group_id="O2" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination 2; n=634, n=632</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months (180 days) after vaccination 2</time_frame>
      <desc>The All Subjects as Treated population included randomized participants who received &gt;=1 dose of study vaccine and had safety follow-up results</desc>
      <group_list>
        <group group_id="E1">
          <title>MMRV (AMP)</title>
          <description>Participants were to received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)</description>
        </group>
        <group group_id="E2">
          <title>MMRV (2006 Process)</title>
          <description>Participants were to receive two 0.5 mL subcutaneous injections of MMRV made with the 2006 manufacturing process</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylcoccal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Exposure via direct contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Exposure via ingestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="574" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="572" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="52" subjects_affected="48" subjects_at_risk="682"/>
                <counts group_id="E2" events="47" subjects_affected="46" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="98" subjects_affected="77" subjects_at_risk="682"/>
                <counts group_id="E2" events="107" subjects_affected="91" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="77" subjects_affected="60" subjects_at_risk="682"/>
                <counts group_id="E2" events="72" subjects_affected="61" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="344" subjects_affected="254" subjects_at_risk="682"/>
                <counts group_id="E2" events="258" subjects_affected="199" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="267" subjects_affected="208" subjects_at_risk="682"/>
                <counts group_id="E2" events="243" subjects_affected="187" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="190" subjects_affected="156" subjects_at_risk="682"/>
                <counts group_id="E2" events="146" subjects_affected="123" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="349" subjects_affected="225" subjects_at_risk="682"/>
                <counts group_id="E2" events="360" subjects_affected="235" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="682"/>
                <counts group_id="E2" events="43" subjects_affected="41" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="65" subjects_affected="55" subjects_at_risk="682"/>
                <counts group_id="E2" events="76" subjects_affected="66" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="177" subjects_affected="128" subjects_at_risk="682"/>
                <counts group_id="E2" events="179" subjects_affected="128" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="72" subjects_affected="56" subjects_at_risk="682"/>
                <counts group_id="E2" events="57" subjects_affected="44" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="47" subjects_affected="40" subjects_at_risk="682"/>
                <counts group_id="E2" events="43" subjects_affected="35" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="210" subjects_affected="159" subjects_at_risk="682"/>
                <counts group_id="E2" events="212" subjects_affected="163" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="52" subjects_affected="44" subjects_at_risk="682"/>
                <counts group_id="E2" events="64" subjects_affected="57" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="113" subjects_affected="87" subjects_at_risk="682"/>
                <counts group_id="E2" events="118" subjects_affected="101" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="78" subjects_affected="58" subjects_at_risk="682"/>
                <counts group_id="E2" events="64" subjects_affected="53" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="76" subjects_affected="62" subjects_at_risk="682"/>
                <counts group_id="E2" events="106" subjects_affected="77" subjects_at_risk="683"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="50" subjects_affected="48" subjects_at_risk="682"/>
                <counts group_id="E2" events="55" subjects_affected="47" subjects_at_risk="683"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

